98%
921
2 minutes
20
Purpose: There is emerging evidence that germline pathogenic/likely pathogenic (P/LP) mutations in cancer predisposition genes (CPGs) increase the risk of subsequent neoplasms (SNs) in childhood cancer survivors. However, clinical application of this observation is hampered by the lack of knowledge regarding subpopulations at risk for SNs who could potentially benefit from genetic screening.
Patients And Methods: Whole-exome sequencing was performed using germline DNA from 499 survivors with SNs (cases) and 625 survivors without (matched controls) in a Children's Oncology Group study. Using conditional logistic regression, we estimated demographic/clinical/therapeutic characteristics and P/LP mutations associated with SN risk. We then randomly partitioned the case-control data set using a 60/40 split to create training and test data, respectively, and developed a clinical risk classifier. Model performance and its improvement with addition of P/LP mutation status was evaluated on the test data using the area under the receiver operating curve (AUC).
Results: We found a 4.26-fold higher odds of SNs among P/LP mutation carriers (95% CI, 2.36 to 7.69). The clinical risk classifier (including sex, primary cancer type and year of diagnosis, exposure to radiation and platinum compounds, and length of follow-up) showed a significant performance improvement with the addition of P/LP mutation status, and P/LP × platinum and P/LP × radiation interactions (AUC increased from 0.79 to 0.82, = .014). Using the clinical risk classifier, we classified survivors at low risk (22%) and moderate-to-high risk (78%) of developing SNs. Overall, 86.4% of the survivors with any P/LP mutations, and all and mutation carriers were partitioned into the moderate-to-high risk group.
Conclusion: These findings provide a risk-based approach for identifying childhood cancer survivors who could be referred for genetic testing, informing surveillance strategies on the basis of refined risk classification.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367065 | PMC |
http://dx.doi.org/10.1200/JCO-25-00542 | DOI Listing |
Vaccine
September 2025
Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Background: Covid-19 vaccines are updated to match circulating strains based on reasoning that better strain-matched immunogenicity should provide better protection. Randomized evidence with disease endpoints to support strain matching is lacking. We evaluated COVID-19 incidence among adults randomized to a second booster of Prototype or Omicron-based vaccines.
View Article and Find Full Text PDFCien Saude Colet
August 2025
Instituto de Medicina Social Hesio Cordeiro, Universidade do Estado do Rio de Janeiro. R. São Francisco Xavier 524, Maracanã. 20550-900 Rio de Janeiro RJ Brasil.
In this article an analysis of the preventive campaigns against cervical cancer (CC) and human papillomavirus (HPV) vaccination developed by the National Cancer Institute (INCA) of the Ministry of Health was conducted, in addition to some campaigns produced by non-governmental organizations and private institutions, from 2014 to 2020. From a socio-anthropological point of view, the objective was to understand how these health technologies trigger and produce gender representations. Seven categories of analysis were developed ("Generationality of care", "Schooling", "Childhood and Youth", "Gamification", "Health risk", "Men's health" and "Neutrality") that permitted discussion of the themes that emerged in graphic pieces.
View Article and Find Full Text PDFNed Tijdschr Geneeskd
September 2025
Reinier de Graaf Gasthuis, afd. Dermatologie, Delft.
This case report describes the presence of an acquirednaevus of Ito on a 78-year-old Dutch male. Naevus of Ito is a blue-grey discolouration that most commonly presents on Asian individuals during childhood. It is exceedingly rare for this naevus to occur later in life in a non-Asian individual.
View Article and Find Full Text PDFHematology
December 2025
Department of Pediatrics, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou Province, People's Republic of China.
Background: Childhood leukaemia remains a major global health challenge and its impact varies significantly by region. Understanding the patterns of incidence, mortality, prevalence, and disability-adjusted life years (DALYs) is crucial for crafting effective public health initiatives and enhancing care outcomes, especially in regions with constrained resources.
Methods: This study evaluates the worldwide, regional, and country-specific effects of childhood leukemia between 1990 and 2021, leveraging data from the Global Burden of Disease (GBD) initiative.
EClinicalMedicine
October 2025
Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, 686 Bay St., Toronto, Ontario, Canada.
Background: While testicular germ cell tumors (TGCT) survival exceeds 90%, many survivors of adult TGCT are at risk for treatment toxicities. Less is known about physical morbidities in children, adolescents, and young adults (CAYA) with TGCT.
Methods: We used the Pediatric Oncology Group of Ontario Networked Information System, the Initiative to Maximize Progress in Adolescent and Young Adult Cancer Therapy, and the Ontario Cancer Registry to identify all CAYA males diagnosed with TGCT from 1992 to 2021 at age 11-21 years in Ontario, Canada.